Showing results (281-290 of 584) with videos related to

Sort By:
Pageof 59
NPJ Precision Oncology|December 18, 2021
Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancerDiana Schaufler, David F Ast, Hannah L Tumbrink, et al.
Molecular Cancer|October 4, 2024
Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX developmentDamien Vasseur, Ludovic Bigot, Kristi Beshiri, et al.
Cancer Treatment Reviews|May 11, 2024
NTRK gene fusion testing and management in lung cancerMatteo Repetto, Marina Chiara Garassino, Herbert H Loong, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 29, 2017
Are we reproducible in measurement of NET liver metastasis?Salma Moalla, Julia Arfi Rouche, Stéphanie Foulon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2007
Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancerPierre Saintigny, Benjamin Besse, Patrice Callard, et al.
Future Oncology (London, England)|December 16, 2021
MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancerByoung Chul Cho, Enriqueta Felip, Hidetoshi Hayashi, et al.
Bulletin Du Cancer|December 10, 2013
Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 patientsSylvestre Le Moulec, Julien Hadoux, Eric Gontier, et al.
JTO Clinical and Research Reports|February 24, 2025
Personalized Therapy in a Patient With EGFR-Mutated NSCLC Developing Sequential CCDC6-RET Fusion and BRAF V600E Mutation as Bypass Resistance MechanismsArianna Marinello, Claudia Parisi, Damien Vasseur, et al.
Lung Cancer (Amsterdam, Netherlands)|November 29, 2024
Validation of the Lung Immune Prognostic Index in patients with untreated advanced non-small cell lung cancer: Post hoc analysis of the IMpower 130, 131 and 150 trialsEdouard Auclin, Matthieu Roulleaux Dugage, Teresa Gorria, et al.
Clinical Lung Cancer|August 16, 2021
PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma PatientsJordi Remon, Nicolas Girard, Silvia Novello, et al.
Pageof 59